Novel incentive-based approaches to adherence

Clinical Trials

Volumn 9, Issue 6, 2012, Pages 689-695

  Kimmel, Stephen E ^a,b   Troxel, Andrea B ^a  

^a UNIVERSITY OF PENNSYLVANIA   (United States)

^b UNIVERSITY OF PENNSYLVANIA   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

WARFARIN;

BEHAVIORAL ECONOMICS; CLINICAL PRACTICE; CLINICAL TRIAL (TOPIC); CONFERENCE PAPER; COST EFFECTIVENESS ANALYSIS; DECISION MAKING; ELECTRONIC PRESCRIBING; FINANCIAL MANAGEMENT; HEALTH BEHAVIOR; HEART ATRIUM FIBRILLATION; HUMAN; INTERNATIONAL NORMALIZED RATIO; PATIENT COMPLIANCE; PRESCRIPTION; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL (TOPIC); STUDY DESIGN;

ANTICOAGULANTS; ECONOMICS, BEHAVIORAL; HUMANS; MEDICATION ADHERENCE; MOTIVATION; RANDOMIZED CONTROLLED TRIALS AS TOPIC; REMINDER SYSTEMS; RESEARCH DESIGN; VENOUS THROMBOEMBOLISM; WARFARIN;

EID: 84871848045     PISSN: 17407745     EISSN: 17407753     Source Type: Journal    
DOI: 10.1177/1740774512453520     Document Type: Conference Paper

References (79)

1. Gibbons RJ, Abrams J, Chatterjee K, et al. ACC/AHA 2002 guidelines update for the management of patients with chronic stable angina: A report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines (Committee to Update the 1999 Guidelines for the Management of Patients with Chronic Stable Angina). Journal of the American College of Cardiology. 2003 ; 41 (1). 159-68 (Pubitemid 36044419)
2. Baigent C, Keech A, Kearney PM, et al. Efficacy and safety of cholesterol-lowering treatment: Prospective meta-analysis of data from 90,056 participants in 14 randomised trials of statins. Lancet. 2005 ; 366 (9493). 1267-78
3. Randomised trial of cholesterol lowering in 4444 patients with coronary heart disease: The Scandinavian Simvastatin Survival Study (4S). Lancet. 1994 ; 344 (8934). 1383-9
4. Sacks FM, Pfeffer MA, Moye LA, et al. The effect of pravastatin on coronary events after myocardial infarction in patients with average cholesterol levels. Cholesterol and Recurrent Events Trial investigators. N Engl J Med. 1996 ; 335 (14). 1001-9 (Pubitemid 26338729)
5. Downs JR, Clearfield M, Weis S, et al. Primary prevention of acute coronary events with lovastatin in men and women with average cholesterol levels: Results of AFCAPS/TexCAPS. Air Force/Texas Coronary Atherosclerosis Prevention Study. JAMA. 1998 ; 279 (20). 1615-22 (Pubitemid 28248586)
6. Prevention of cardiovascular events and death with pravastatin in patients with coronary heart disease and a broad range of initial cholesterol levels. The Long-Term Intervention with Pravastatin in Ischaemic Disease (LIPID) Study Group. N Engl J Med. 1998 ; 339 (19). 1349-57
7. Ridker PM, Danielson E, Fonseca FA, et al. Reduction in C-reactive protein and LDL cholesterol and cardiovascular event rates after initiation of rosuvastatin: A prospective study of the JUPITER trial. Lancet. 2009 ; 373 (9670). 1175-82
8. Jackevicius CA, Mamdani M, Tu JV. Adherence with statin therapy in elderly patients with and without acute coronary syndromes. JAMA. 2002 ; 288 (4). 462-7 (Pubitemid 34787477)
9. Newby LK, LaPointe NM, Chen AY, et al. Long-term adherence to evidence-based secondary prevention therapies in coronary artery disease. Circulation. 2006 ; 113 (2). 203-12
10. Benner JS, Glynn RJ, Mogun H, et al. Long-term persistence in use of statin therapy in elderly patients. JAMA. 2002 ; 288: 455-61 (Pubitemid 34787476)
11. Gislason GH, Rasmussen JN, Abildstrom SZ, et al. Long-term compliance with beta-blockers, angiotensin-converting enzyme inhibitors, and statins after acute myocardial infarction. Eur Heart J. 2006 ; 27 (10). 1153-8
12. Am Heart J. Kulkarni SP Alexander KP Lytle B Heiss G Peterson ED, ed. 2006: 185-91.
13. Simpson E, Beck C, Richard H, Eisenberg MJ, Pilote L. Drug prescriptions after acute myocardial infarction: Dosage, compliance, and persistence. Am Heart J. 2003 ; 145 (3). 438-44 (Pubitemid 36390489)
14. Hudson M, Richard H, Pilote L. Parabolas of medication use and discontinuation after myocardial infarction-are we closing the treatment gap?. Pharmacoepidemiol Drug Saf. 2007 ; 16 (7). 773-85 (Pubitemid 47180366)
15. Eagle KA, Kline-Rogers E, Goodman SG, et al. Adherence to evidence-based therapies after discharge for acute coronary syndromes: An ongoing prospective, observational study. Am J Med. 2004 ; 117 (2). 73-81 (Pubitemid 38953725)
16. Ho PM, Magid DJ, Masoudi FA, McClure DL, Rumsfeld JS. Adherence to cardioprotective medications and mortality among patients with diabetes and ischemic heart disease. BMC Cardiovasc Disord. 2006 ; 6: 48
17. Blackburn DF, Dobson RT, Blackburn JL, et al. Adherence to statins, beta-blockers and angiotensin-converting enzyme inhibitors following a first cardiovascular event: A retrospective cohort study. Can J Cardiol. 2005 ; 21 (6). 485-8 (Pubitemid 40823600)
18. Ho PM, Rumsfeld JS, Masoudi FA, et al. Effect of medication nonadherence on hospitalization and mortality among patients with diabetes mellitus. Arch Intern Med. 2006 ; 166 (17). 1836-41 (Pubitemid 44455165)
19. Wei L, Wang J, Thompson P, et al. Adherence to statin treatment and readmission of patients after myocardial infarction: A six year follow up study. Heart. 2002 ; 88 (3). 229-33 (Pubitemid 34913500)
20. Wei L, Flynn R, Murray GD, MacDonald TM. Use and adherence to beta-blockers for secondary prevention of myocardial infarction: Who is not getting the treatment?. Pharmacoepidemiol Drug Saf. 2004 ; 13 (11). 761-6 (Pubitemid 39496897)
21. Rasmussen JN, Chong A, Alter DA. Relationship between adherence to evidence-based pharmacotherapy and long-term mortality after acute myocardial infarction. JAMA. 2007 ; 297 (2). 177-86 (Pubitemid 46089734)
22. Ho PM, Spertus JA, Masoudi FA, et al. Impact of medication therapy discontinuation on mortality after myocardial infarction. Arch Intern Med. 2006 ; 166 (17). 1842-7 (Pubitemid 44455166)
23. Hyers TM, Agnelli G, Hull RD, et al. Antithrombotic therapy for venous thromboembolic disease. Chest. 1998 ; 114: 561S - 78S (Pubitemid 28535781)
24. Laupacis A, Boysen G, Connolly S, Ezekowitz M, Hart R, James K, et al. Risk factors for stroke and efficacy of antithrombotic therapy in atrial fibrillation. Analysis of pooled data from five randomized controlled trials. Arch Intern Med. 1994 ; 154 (13). 1449-57
25. Laupacis A, Albers G, Dalen J, et al. Antithrombotic therapy in atrial fibrillation. Chest. 1998 ; 114: 579S - 89S (Pubitemid 28535782)
26. Lancet. Petersen P Boysen G Godtfredsen J Andersen ED Andersen B, ed. 1989: 175-9.
27. EAFT (European Atrial Fibrillation Trial) Study Group. Lancet. 1993 ; 342 (8882). 1255-62
28. Gullov AL, Koefoed BG, Petersen P, et al. Fixed minidose warfarin and aspirin alone and in combination vs adjusted-dose warfarin for stroke prevention in atrial fibrillation: Second Copenhagen Atrial Fibrillation, Aspirin, and Anticoagulation Study. Arch Intern Med. 1998 ; 158 (14). 1513-21 (Pubitemid 28340984)
29. Chiquette E, Amato MG, Bussey HI. Comparison of an anticoagulation clinic with usual medical care: Anticoagulation control, patient outcomes, and health care costs. Arch Intern Med. 1998 ; 158 (15). 1641-7 (Pubitemid 28371187)
30. Goldhaber SZ. Pulmonary embolism. N Engl J Med. 1998 ; 339 (2). 93-104 (Pubitemid 28304885)
31. Barritt DW, Jordan SC. Anticoagulant drugs in the treatment of pulmonary embolism. A controlled trial. Lancet. 1960 ; 1: 1309-12
32. Hirsh J, Fuster V. Guide to anticoagulant therapy. Part 2: Oral anticoagulants. American Heart Association. Circulation. 1994 ; 89 (3). 1469-80 (Pubitemid 24076569)
33. Brigden M, Kay C, Le A, Graydon C, McLeod B. Audit of the frequency and clinical response to excessive oral anticoagulation in an out-patient population. Am J Hematol. 1998 ; 59: 22-7 (Pubitemid 28395002)
34. Kearon C, Gent M, Hirsh J, et al. A comparison of three months of anticoagulation with extended anticoagulation for a first episode of idiopathic venous thromboembolism. N Engl J Med. 1999 ; 340 (12). 901-7 (Pubitemid 29141050)
35. Landefeld CS, Beyth RJ. Anticoagulant-related bleeding: Clinical epidemiology, prediction, and prevention. Am J Med. 1993 ; 95 (3). 315-28 (Pubitemid 23270290)
36. McMahan DA, Smith DM, Carey MA, Zhou XH. Risk of major hemorrhage for outpatients treated with warfarin. J Gen Intern Med. 1998 ; 13 (5). 311-6 (Pubitemid 28242293)
37. Landefeld CS, Goldman L. Major bleeding in outpatients treated with warfarin: Incidence and prediction by factors known at the start of outpatient therapy. Am J Med. 1989 ; 87 (2). 144-52 (Pubitemid 19201634)
38. Doshi JA, Zhu J, Lee B, Kimmel S, Volpp KG. Impact of a prescription copayment increase on lipid lowering medication adherence in Veterans. Circulation. 2009 ; 119: 390-7
39. Chernew ME, Shah MR, Wegh A, et al. Impact of decreasing copayments on medication adherence within a disease management environment. Health Aff. 2008 ; 27 (1). 103-12 (Pubitemid 351198595)
40. Chernew ME, Rosen AB, Fendrick AR. Value-based insurance design. Health Aff. 2007 ; 26 (2). w195-203
41. Tversky A, Kahneman DR. Loss aversion in riskless choice: A reference-dependent model. Q J Econ. 1991 ; 106 (4). 1039-61
42. Marcus AC, Kaplan CP, Crane LA, et al. Reducing loss-to-follow-up among women with abnormal Pap smears. Results from a randomized trial testing an intensive follow-up protocol and economic incentives. Med Care. 1998 ; 36 (3). 397-410 (Pubitemid 128456382)
43. Stevens-Simon C, O'Connor P, Bassford K. Incentives enhance postpartum compliance among adolescent prenatal patients. J Adolesc Health. 1994 ; 15 (5). 396-9 (Pubitemid 24239822)
44. Chaisson RE, Keruly JC, McAvinue S, Gallant JE, Moore RD. Effects of an incentive and education program on return rates for PPD test reading in patients with HIV infection. J Acquir Immune Defic Syndr Hum Retrovirol. 1996 ; 11 (5). 455-9 (Pubitemid 26135082)
45. Kane RL, Johnson PE, Town RJ, Butler M. A structured review of the effect of economic incentives on consumers' preventive behavior. Am J Prev Med. 2004 ; 27 (4). 327-52 (Pubitemid 39370913)
46. Higgins ST, Silverman K Motivating Behavior Change among Illicit Drug Abusers: Research on Contingency Management Interventions. Washington, DC: American Psychological Association ; 1999:
47. Higgins ST The Economic Analysis of Substance Use and Abuse. Chaloupka FJ Grossman M Bickel WK Saffer H, ed. Cambridge, MA: NBER ; 1999: 157-74.
48. Skinner BF Cumulative Record: A Selection of Papers. 3 rd edn). Meredith, New York, 1972. New York: Meredith ; 1972:
49. Bains N, Pickett W, Hoey J. The use and impact of incentives in population-based smoking cessation programs: A review. Am J Health Promo. 1998 ; 12: 307-20 (Pubitemid 29249310)
50. Zeelenberg M, Pieters R. Consequences of regret aversion in real life: The case of the Dutch postcode lottery. Organ Behav Hum Dec. 2004 ; 93 (2). 155-68 (Pubitemid 38421818)
51. Ainslie G. Specious reward: A behavioral theory of impulsiveness and impulse control. Psychol Bull. 1975 ; 82: 463-96
52. Thaler RH. Some empirical evidence on time inconsistency. Rev Econ Stud. 1981 ; 23: 165-80
53. Loewenstein G, Prelec D. Anomalies in intertemporal choice: Evidence and an interpretation. Quart J Econ. 1992 ; 107: 573-97
54. Kirby K. Bidding on the future: Evidence against normative discounting of delayed rewards. J Exp Psychol Gen. 1997 ; 126: 54-70
55. Camerer C, Ho T-H. Experience-weighted attraction learning in normal form games. Econometrica. 1999 ; 67: 837-74
56. Loewenstein G, Weber EU, Hsee CK, Welch N. Risk as feelings. Psychol Bull. 2001 ; 127 (2). 267-86 (Pubitemid 33696171)
57. Connolly T, Butler DU. Regret in economic and psychological theories of choice. J Behav Dec Making. 2006 ; 19 (2). 148-58
58. Chapman GB, Coups EJ. Emotions and preventive health behavior: Worry, regret, and influenza vaccination. Health Psychol. 2006 ; 25 (1). 82-90 (Pubitemid 43214385)
59. Thaler RH, Tversky A, Kahneman AS. The effect of myopia and loss aversion on risk taking: An experimental test. Quart J Econ. 1997 ; 112: 647-61 (Pubitemid 127077774)
60. Rizzo JA, Zeckhauser RJ. Reference incomes, loss aversion, and physician behavior. Rev Econ Stat. 2003 ; 85 (4). 909-22 (Pubitemid 37417025)
61. Osterberg L, Blaschke T. Adherence to medication. N Engl J Med. 2005 ; 353 (5). 487-97 (Pubitemid 41127293)
62. Haynes RB, Wang E, da Mota-Gomes M. A critical review of interventions to improve compliance with prescribed medications. Pat Educ Counsel. 1987 ; 10: 155-66
63. Epstein L, Cluss P. A behavioral medicine perspective on adherence to long-term medical regimens. J Consult Clin Psychol. 1982 ; 50: 950-71 (Pubitemid 13168570)
64. Chen A. Noncompliance in community psychiatry: A review of clinical interventions. Hosp Com Psych. 1991 ; 42 (3). 282-7
65. Zygmunt A, Olson M, Boyer C, Mechanic D. Interventions to improve medication adherence in schizophrenia. Am J Psychiatry. 2002 ; 159: 1653-64
66. Ruskin PE, Van der Wende J, Clark CR, et al. Feasibility of using the Med-eMonitor™ system in the treatment of schizophrenia: A pilot study. Drug Infor J. 2003 ; 38: 1-8
67. Prochaska JO, Butterworth S, Redding CA, et al. Initial efficacy of MI, TTM tailoring and HRI's with multiple behaviors for employee health promotion. Prev Med. 2008 ; 46 (3). 226-31
68. Greene GW, Rossi SR, Rossi JS, et al. Dietary applications of the stages of change model. J Am Diet Assoc. 1999 ; 99 (6). 673-8 (Pubitemid 29254873)
69. Murphy SA. An experimental design for the development of adaptive treatment strategies. Stat Med. 2005 ; 24 (10). 1455-81 (Pubitemid 40716347)
70. Lavori PW, Dawson R, Rush AJ. Flexible treatment strategies in chronic disease: Clinical and research implications. Biol Psych. 2000 ; 48 (6). 605-14
71. Lavori PW, Dawson R. Dynamic treatment regimes: Practical design considerations. Clin Trials. 2004 ; 1 (1). 9-20
72. Murphy SA, van der Laan MJ, Robins JM. Marginal mean models for dynamic regimes. JASA. 2001 ; 96: 1410-23 (Pubitemid 33695590)
73. Bembom O, van der Laan MJ. Statistical methods for analyzing sequentially randomized trials. J Natl Cancer Inst. 2007 ; 99: 1577-82
74. Collins LM, Murphy SA, Strecher V. The multiphase optimization strategy (MOST) and the sequential multiple assignment randomized trial (SMART): New methods for more potent eHealth interventions. Am J Prev Med. 2007 ; 32: S112-18
75. Deng K, Pineau J, Murphy SA. Active learning for developing personalized treatment. Proceedings of the Twenty-Seventh Conference Annual Conference on Uncertainty in Artificial Intelligence (UAI-11) ; 2011 Barcelona, Spain ; 2011. 161.
76. Deng K, Pineau J, Murphy SA. Active learning for personalizing treatment. 2011 IEEE Symposium on Adaptive Dynamic Programming and Reinforcement Learning (ADPRL) ; ;. 32.
77. Lizotte D, Bowling M, Murphy SA. Efficient reinforcement learning with multiple reward functions for randomized controlled trial analysis. Proceedings of the 27th International Conference on Machine Learning ; 2010 Haifa, Israel ; 2010. 695.
78. Shaw J. Is it acceptable for people to be paid to adhere to medication? No. BMJ. 2007 ; 335: 233
79. Halpern SD, Madison KM, Volpp KG. Patients as mercenaries? The ethics of using financial incentives in the war on unhealthy behaviors. Circ Cardiovasc Qual Outcomes. 2009 ; 2: 514-6